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Abstract: Background: The event of X chromosome inactivation induced by XIST, which is
physiologically observed in females, is retained in testicular germ cell tumors (TGCTs), as a result
of a supernumerary X chromosome constitution. X chromosome inactivation also occurs in male
germline, specifically during spermatogenesis. We aimed to analyze the promoter methylation
status of XIST in a series of TGCT tissues, representative cell lines, and testicular parenchyma.
Methods: Two independent cohorts were included, comprising a total of 413 TGCT samples, four
(T)GCT cell lines, and 86 testicular parenchyma samples. The relative amount of methylated and
demethylated XIST promoter fragments was assessed by quantitative methylation-specific PCR
(qMSP) and more sensitive high-resolution melting (HRM) methylation analyses. Results: Seminomas
showed a lower amount of methylated XIST fragments as compared to non-seminomas or normal
testis (p < 0.0001), allowing for a good discrimination among these groups (area under the curve 0.83
and 0.81, respectively). Seminomas showed a significantly higher content of demethylated XIST as
compared to non-seminomas. The percentage of demethylated XIST fragment in cell lines reflected
their chromosomal constitution (number of extra X chromosomes). A novel and strong positive
correlation between the Johnsen’s score and XIST demethylation was identified (r = 0.75, p < 0.0001).
Conclusions: The X chromosome inactivation event and demethylated XIST promoter are promising
biomarkers for TGCTs and for assessing spermatogenesis quality.
Keywords: molecular biomarkers; testicular germ cell tumors; spermatogenesis; methylation;
XIST promoter
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1. Introduction
Germ cell tumors (GCTs) are remarkable developmental cancers, meaning that they recapitulate
the various steps of embryonic and germ cell development, reflecting the main characteristics of their
cells of origin [1]. They can arise not only in the gonads (testis and ovary) but also in extragonadal
sites along the midline of the body, and they can aﬄict a wide age range of patients, from children to
young adults. Epigenetic deregulation plays an important role in their genesis [2], which is in line
with this developmental model, since few recurrent mutations are found in these neoplasms. Instead,
a “genvironmental” model underlies tumorigenesis [3], and helps to explain the epidemiology and
classification of these tumors (from type 0 to type VI tumors) [1,4,5].
Among the heterogeneous group of GCTs, the testicular germ cell tumors (TGCTs) are the most
common. The type II tumors are the most frequent and clinically relevant [6]. They derive from a
common precursor lesion, germ cell neoplasia in situ (GCNIS), and are divided into the following two
major and relevant categories, with distinct clinical behavior: the seminomas (SEs) and the various
non-seminoma (NS) subtypes, including embryonal carcinoma (EC), (postpubertal-type) yolk sac tumor
(YST), choriocarcinoma (CH), and (postpubertal-type) teratoma (TE) [7]. Specifically, for these tumors,
developmental biology has an invaluable impact by driving the identification of relevant disease
biomarkers. On the one hand, the currently available serum markers of the disease, (alpha fetoprotein
[AFP] and human chorionic gonadotropin subunit beta [β-HCG]), normally expressed during
embryogenesis, show important limitations. On the other hand, the pluripotency factors constitute the
basis of disease classification but are only informative based on tissue sample investigations. Finally,
and more recently, a set of embryonic microRNAs that regulate development have shown outstanding
performance as liquid biomarkers, bringing them closer to clinical introduction [8].
In this developmental perspective, another specific event of these neoplasms that might be used as
a molecular biomarker is the X chromosome inactivation (or lyonization, described by Mary Lyon [9]).
Indeed, this biological process occurs physiologically in females (XX) and is limited to germ cells in the
male, is in fact recapitulated in all variants of type II TGCTs, as they show a gain of the X chromosome
(due to whole genome duplication as an early pathogenetic event). This process of X chromosome
inactivation involves XIST, a long non-coding RNA (lncRNA) which facilitates this process on extra X
chromosomes by inducing a complex cascade of chromatin changes, including methylation and histone
modifications [10,11]. XIST expression was indeed documented in these tumors (particularly in SEs),
and allowed for the tolerance of supernumerary X chromosomes [12]. Later, Kawakami et al. [13]
studied in detail the XIST promoter (by bisulfite sequencing, followed by conventional polymerase
chain reaction (PCR) with primers specific for the methylated and demethylated XIST promoter),
finding that region IV was frequently demethylated in TGCTs (again, especially in SEs) [14]. In addition,
importantly, they demonstrated no evidence of this demethylated fragment in somatic male cancers.
Exploring these findings in larger cohorts, with quantitative and more sensitive methodology and in
liquid biopsy setting could be of clinical value, complementing other biomarkers for diagnosis and
follow-up of type II TGCT patients [15]. To date, no such studies have been pursued.
Infertility is a frequent side effect from cancer treatments that severely impacts the quality of life
of cancer survivors. Type II TGCTs, and GCTs in general, have an overall good prognosis and aﬄict
mainly young adults, with long life expectancy, so fertility issues are a major concern [16]. Studies
demonstrated that XIST is re-expressed transiently, in waves, during spermatogenesis around the
time cells enter meiosis [17,18]. It is believed that X chromosome inactivation constitutes a protecting
mechanism necessary for normal spermatogenesis, forming the so-called “XY body” and avoiding
aberrant crosslinks among the sex chromosomes, with cells failing to do so being eliminated by
apoptosis [19]. One of the ways of evaluating the efficiency of spermatogenesis is by applying the
Johnsen’s score on histological samples of testicular parenchyma [20]. However, this analysis is
laborious and, importantly, not very reproducible and subjected to sampling issues [21]. Novel markers
for reliably estimating the quality of spermatogenesis in male individuals allowing for better selection
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for testicular sperm extraction (TESE) or other interventions are desirable, although not present so
far [22].
The aim of this work is to explore the role of demethylated and methylated XIST promoter as a
candidate biomarker for both TGCTs as well as extensiveness of spermatogenesis.
2. Results
2.1. Methylated XIST Promoter in TGCTs
First, we first focused on the methylated XIST promoter fragment, specifically in our discovery
cohort (clinicopathological features depicted in Supplementary Table S1). Considering all 250 TGCT
tumor samples, they showed a significantly lower relative amount of methylated XIST fragment as
compared to testicular parenchyma samples (p < 0.0001). This difference occurred at the expense of
SEs, being more remarkable when selecting all SE components (pure and present in mixed tumors)
(p < 0.0001) and even more when selecting only the pure SE samples (p < 0.0001). In fact, no significant
differences in the relative amount of methylated XIST were found as compared with NS samples and
the testicular parenchyma cohort (Figure 1).
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testicular parenchyma samples and (A) all testicular germ cell tumors (TGCTs), (B) all seminomas 
(SEs), (C) only pure SEs, and (D) all non-seminomas (NSs). **** indicate p < 0.0001. Abbreviations: 
NS—non-seminoma; SE—seminoma; TGCT—testicular germ cell tumor. 
Moreover, SEs exhibited a significantly lower amount of methylated XIST fragment as compared 
with NS components (p < 0.0001) and there were also significant differences in the amount of 
methylated XIST fragment among the various individual tumor subtypes (p < 0.0001). When each of 
the five histological tumor components were considered individually, SE subtype showed a lower 
amount of this fragment in comparison with EC and YST (adjusted p-value < 0.0001) and TE (adjusted 
p-value < 0.01) (Figure 2). 
The relative amount of the methylated XIST fragment in SE cases was significantly lower as 
compared to patients with no GCT pathology, cases with NS, and specifically cases with pure EC (p 
< 0.0001, p < 0.0001, p < 0.01, respectively). Methylated XIST fragment relative amount allowed for a 
good discrimination among these groups, with an area under the curve (AUCs) of 0.81, 0.83 and 0.75, 
respectively (Figure 3). This allowed for a good performance in the discrimination, with sensitivity, 
specificity, and accuracy consistently above 70% (Table 1). 
Figure 1. Methylated XIST fragment relative amounts in testicular germ cell tumors and testicular
parenchyma of the discovery cohort. Relative amounts of the methylated XIST fragment among
testicular parenchyma samples and (A) all testicular germ cell tumors (TGCTs), (B) all seminomas
(SEs), (C) only pure SEs, and (D) all non-seminomas (NSs). **** indicate p < 0.0001. Abbreviations:
NS—non-seminoma; SE—seminoma; TGCT—testicular germ cell tumor.
Moreover, SEs exhibited a significantly lower amount of methylated XIST fragment as compared
with NS components (p < 0.0001) nd there were also significant differences in the amount of methylated
XIST fragment among the various indivi ual tumor subtypes (p < 0.0001). When each of the five
histologic l tumor components were considered i i i lly, SE subtype howed a lower amount
of t is fragment in comparison with EC and YST (adjusted p- al e < 0.0001) and TE (adjusted
p-v lue < 0.01) (Figure 2).
The relative amo nt of the methylated XIST fragment in SE cases was significantly lower as
compared to p tients with n GCT pat ology, cases with NS, a d specifically cases with pure EC
(p < 0.0001, p < 0.0001, p < 0.01, respectively). Methylated XIST fragment relative amount allowed for
a good discrimination among these groups, with an area under the curve (AUCs) of 0.81, 0.83 and 0.75,
respectively (Figure 3). This allowed for a good performance in t e discrimination, with sensitivity,
specificity, and accuracy consistently above 70% (Table 1).
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Figure 2. Methylated XIST fragment relative amounts among various tumor subtypes of the
discovery cohort. Relative amounts of the methylated XIST fragment in (A) seminoma and
non-seminoma and (B) all histological subtypes. **** indicates p < 0.0001 and ** indicates
p < 0.01. Abbreviations: CH—choriocarcinoma; EC—embryonal carcinoma; NS—non-seminoma;
SE—seminoma; TE—postpubertal-type teratoma; YST—postpubertal-type yolk sac tumor.
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Relative amounts of the methylated XIST fragment in pure se ino a patients and (A) no evidence of
TGCT, respective receiving operator characteristic (ROC) curve in (B); (C) NS, respective ROC curve in
(D); and (E) only pure embryo al carcinoma (EC), respective ROC curve in (F). **** indicates p < 0.0001
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Table 1. Discrimination performance parameters for XIST methylated fragment.
Context. AUC (95% CI) Sensitivity(%)
Specificity
(%) PPV (%) NPV (%)
Accuracy
(%)
SE vs. non-GCT cases 0.81 (0.74–0.88) 73.5 74.1 81.3 64.5 73.7
SE vs. NS cases 0.83 (0.76–0.89) 77.1 80.8 82.1 75.6 78.8
SE vs. EC cases 0.75 (0.54–0.95) 84.3 70.0 95.9 35.0 82.8
Abbreviations: AUC—area under the curve; CI—confidence interval; PPV—positive predictive value;
NPV—negative predictive value.
No significant correlation was found between the relative amount of methylated XIST fragment
and the age of non-GCT, SE, and NS patients, respectively (p = 0.855, p = 0.064, and p = 0.761). Moreover,
we found no significant association with patients’ stage, metastatic dissemination or the International
Germ Cell Cancer Collaborative Group (IGCCCG) category (data not shown), which is in line with
publicly available TCGA data, showing hypermethylation of the XIST promoter both in SE as well as
in NS. These results are likely biased due to non-tumor contamination as reported before, found to be
present both in SE as well as in NS [23]. No results on demethylation specifically have been reported in
the TCGA dataset [24].
2.2. Demethylated XIST Promoter in TGCTs, GCNIS, and in (T)GCT Cell Lines
We then focused on the demethylated XIST promoter fragment, which we studied in two
independent cohorts. Considering all tumor samples in the discovery cohort, no significant differences
in the relative amount of the demethylated fragment were depicted between tumor samples (as a
whole or grouped as SE/NS) and the testicular parenchyma samples (Supplementary Figure S1).
However, SE samples were found to exhibit a higher relative amount of the demethylated XIST
fragment as compared with NS (p < 0.001), with the same occurring when compared individually to
EC and TE tumor subtypes (adjusted p-value < 0.05, Figure 4).
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Figure 4. De ethylated XIST frag ent relative a ounts among various tumor subtypes of
the discovery cohort. Relative amounts of the demethylated XIST fragment in (A) seminoma
and non-seminoma and (B) all histological subtypes. *** indicates p < 0.001, * indicates p
< 0.05. Abbreviations: CH—choriocarcinoma; EC—embryonal carcinoma; NS non-seminoma;
SE—seminoma; TE—postpubertal-type teratoma; YST—postpubertal-type yolk sac tumor.
Again, when focusing on the TGCT cases, SE showed a significantly higher amount of XIST
demethylated fragment as compared to EC (p < 0.01, Figure S2). Similar to the methylated fragment,
we found no significant association between the amount of demethylated XIST and patients’ stage,
metastatic dissemination or the IGCCCG category (data not shown).
We then pursued validation and further extension of our findings in a second (validation) cohort
(clinicopathological details of this second cohort available in Supplementary Table S2). The percentage
of demethylated XIST was significantly higher in SE as compared with NS (p < 0.0001). Additionally,
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there were also significant differences in the percentage of XIST demethylation among individual
subtypes (p < 0.0001). SE displayed significantly higher percentage of demethylation of XIST promoter
as compared with mixed tumors (adjusted p-value 0.0015), EC (adjusted p-value 0.0439), and CH
(adjusted p-value 0.0212) (Figure 5). Importantly, some degree of demethylation of XIST promoter
was able to be detected in 137 of 146 (93.8%) TGCTs; only nine tumor samples (three SE and six NS,
including three mixed tumors, one pure EC, one pure YST, and one pure TE) showed absence of
demethylated XIST.Cancers 2019, 11, x FOR PEER REVIEW 6 of 16 
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Figure 5. Demethylated XIST fragment percentage among various tumor subtypes (validation cohort).
(A) Percentage of demethylated XIST fragment in seminoma and non-se inoma and (B) percentage of
demethylated XIST fragment among all histological subtypes. **** indicates p < 0.0001, *** indicates
p < 0.001, ** indicates p < 0.01, and * indicates p < 0.05. Abbreviations: CH—choriocarcinoma;
EC—embryonal carcinoma; NS—non-seminoma; SE—seminoma; TE—postpubertal-type teratoma;
YST—postpubertal-type yolk sac tumor.
Moreover, demethylated XIST was also detected in 16 of 17 (94.1%) GCNIS lesions. Despite the
reported crescent XIST expression in cases with increasingly more GCNIS content [12], we did not
find the same positive correlation between the extent of GCNIS and the degree of XIST demethylation
(data not shown). However, the percentage of demethylated XIST was significantly lower in GCNIS
lesions as compared with overt SE (p = 0.0001, Figure 6).
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Figure 6. Demethylated XIST fragment percentage in germ cell neoplasia in situ (GCNIS) samples.
Percentage of demethylated XIST fragment in GCNIS and seminoma. *** indicates p < 0.001 and **
indicates p < 0.01. Abbreviations: GCNIS—germ cell neoplasia in situ; SE—seminoma.
Regarding (T)GCT cell lines, demethylated XIST was detected in all four cell lines. The percentage
of demethylated XIST was significantly higher in NT2 as compared with the remaining cell lines
(adjust d p-values of 0.0079, 0.0021, and 0.0108 as compared with TCam-2, NCCIT, and 2102Ep,
respectiv ly) (Figure 7). This is in line with previous karyotype findings reported before with NT2
cells showing three X chromosomes compared to two in 2102Ep nd NCCIT.
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Figure 7. Demethylated XIST fragment percentage in germ cell tumor cell ines. ** indicates p < 0. 1
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2.3. Demethylated XIST Promoter in Testicular Parenchyma
Given the knowledge on XIST expression during spermatogenesis around the time germ
cells enter meiosis, we set out to study its promoter demethylation in two independent testicular
parenchyma cohorts with diverse spermatogenesis efficiency as reported by the Johnsen’s score. The
clinicopathological features of the testicular parenchyma discovery series are depicted in Supplementary
Table S3. We found a significant and strong positive correlation between the relative levels of
demethylated XIST promoter and the Johnsen’s score attributed by the pathologist (rs = 0.75, p < 0.0001).
Hence, we categorized our testicular parenchyma series into “Johnsen’s score <4” (premeiotic germ
cells only) and “Johnsen’s score ≥4” (postmeiotic germ cells present). Samples with Johnsen’s score <4
showed almost absent demethylated XIST fragment (in all except one case), which was significantly
lower as compared with those with a score ≥4 (p < 0.0001, Figure 8). Demethylated XIST fragment was
able to discriminate among testicular parenchyma with a higher or lower (i.e., <4 or ≥4) Johnsen’s
score with an AUC of 0.87 (Figure 8). This allowed for a good performance in discriminating between
these two groups of spermatogenesis quality, namely a 100% specificity (Table 2).Cancers 2019, 11, x FOR PEER REVIEW 8 of 16 
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Table 2. Performance parameters for XIST demethylated fragment in discriminating distinct Johnsen’s
score categories.
Context. AUC (95% CI) Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
JS ≥ 4 vs. JS < 4 0.87 (0.77-0.97) 75.7 100 100 60.9 82.4
Abbreviations: AUC—area under the curve; CI—confidence interval; JS—Johnsen’s score; PPV—positive predictive
value; NPV—negative predictive value.
We pursued validation of our findings in a second independent cohort (description of this cohort
is depicted in Supplementary Table S4). The percentage of demethylated XIST was again significantly
higher in testicular biopsies with a Johnsen’s score ≥4 as compared to those with scores <4 (p < 0.0001).
It allowed for a good discrimination between these two subgroups, with an AUC of 0.89 (Figure 8),
confirming our previous data.
3. Discussion
GCTs are remarkable for their intimate connection with developmental biology. They reflect stages
of germ cell and embryonic development, and the (epigenetic) events that take place during these
processes [1]. The more profound understanding of this link with biology propelled the recent changes
in classification of these tumors [25], and also contributed to uncovering the disease biomarkers
available to date [8]. We do believe that exploring this connection between development and GCTs is
the way to go when it comes to finding novel clinically relevant biomarkers.
In this setting, the event of X chromosome inactivation by XIST is an attractive target, since besides
its physiological occurrence in females (karyotypically XX) [26], it is also maintained in the case of
TGCTs. This lncRNA (called X-inactive specific transcript) is mapped in a chromosomal region called
X chromosome inactivation center (XIC) and, in females, its expression is activated when in cis, leading
to a series of chromatin alterations that include methylation and histone modifications, resulting in
silencing of the excessive X chromosome material (Supplementary Figure S3) [11,27]. Then, in females,
the inactive XIST allele is found to be methylated, while the other copy is demethylated, allowing for
XIST lncRNA expression and subsequent XIST-mediated silencing of the redundant X chromosome
genes [28]. On the other hand, in males, XIST is not expressed (i.e., both alleles are found to be
methylated) in somatic cells (given that there is no need for compensating for redundant chromosome
dosage, being males karyotypically XY), while it is expressed in the germ cell lineage [17]. In addition,
in TGCTs, XIST is found to be expressed in tumor cells given the supernumerary X chromosomes, due
to the initial step of polyploidization. Looijenga and collaborators showed in 1997 [12] that all type II
TGCTs exhibited XIST expression, and found it to be consistent with karyotypic alterations showing
gain of chromosome X.
Subsequent works have demonstrated quite convincingly the existence of X chromosome gains
in TGCTs, both SE and NS alike, and XIST expression in both tumor types [12,29]. Kawakami et al.
reported a higher frequency of XIST expression in SE as compared to NS (85% vs. 25%) [29], although
Looijenga et al. demonstrated XIST expression in all TGCTs, in a way consistent with the X chromosome
content [12]. Following up on these works, and recognizing the potential to regulate XIST promoter by
methylation, Kawakami and coworkers studied in depth the promoter of XIST by means of bisulfite
sequencing, finding 56 CpG sites and dividing the 5′ end into regions I to VI [13]. As region IV was
found to be frequently demethylated it was selected for further validation using conventional PCR,
widely available at the time. Despite a limited cohort (n = 18 SE and n = 13 NS), they detected the
demethylated XIST fragment in all SEs and in 92% of NSs. Moreover, they demonstrated detection of
demethylated XIST in 71% and 55% of plasma samples from SE and NS patients, respectively. In a
similar fashion, they also detected the methylated XIST fragment in several samples, always more
frequently in NS as compared to SE (77% and 45% of NS tissues/plasma samples vs. 61% and 43% of
SE tissues/plasma samples). Our results in two independent cohorts of 250 and 146 TGCT samples
(the largest analyzed, thus far) are perfectly in line with these, and further extend them by the use
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of quantitative approaches, instead of mere “presence” or “absence” of methylated or demethylated
signal. In our cohort, SEs disclosed a significantly lower relative amount of XIST methylated fragment
(Figure 2) and a significantly higher relative amount or percentage of XIST demethylated fragment
(Figures 4 and 5), compatible with findings of Ushida et al. [14]. As well, this was maintained even
when considering all individual histological subtypes, which was an analysis not performed thus
far. Focusing on the relative methylated XIST fragment might be misleading since it might also be
due to some contamination from somatic cells in the tissue such as lymphocytes. An issue that was
demonstrated by us and others in previous works [23]. In spite of this limitation, SEs showed a
significantly lower amount of methylated XIST fragment as compared to patients with no (T)GCTs,
with NS or specifically with pure EC, allowing for a good discrimination power among these subgroups
of patients (Figure 3, Table 1). The absence of associations with clinical variables might indicate that
the methylation status of XIST relates more to the defined (developmental) biology of these tumors,
limiting its value as a prognostic biomarker, although diagnostically of interest.
Previous works have shown expression of XIST in GCNIS, which was more easily detected with
increasing proportion of GCNIS-affected parenchyma, seeming to reflect evolution in the extent of
this precursor lesion [12]. Our results are in line with those findings, since demethylated XIST was
detected in 16 of 17 tested samples. In addition, the percentage of demethylation was significantly
higher in pure SEs as compared with GCNIS (Figure 6), which makes sense in that GCNIS is the direct
precursor of SE, in line with the so-called default pathway [7].
Regarding (T)GCT cell lines, it has been demonstrated that they also show XIST expression (in
consonance with multiple copies of the X chromosome), although with some variation among cell
lines [12]. While Kawakami et al. found XIST expression in the SE-like cell line TCam-2 but not in
the NS-like cell lines ITO-II and NEC8 [29], Looijenga et al. indeed observed XIST expression as
well in the most commonly used and by far better characterized NS-derived cells (NCCIT, NT2, and
2102Ep) [12]. This is again in accordance with our data, showing that demethylated XIST was detected
in all cell lines tested (both SE-like TCam-2 and NS-derived NCCIT, NT2, and 2102Ep), compatible
with XIST expression, although with some variation in distinct cells (Figure 7). Our data show a
significantly higher percentage of XIST demethylation in NT2 cells (around 70% to 80%) as compared
to 2102Ep and NCCIT (around 40% to 50%). This is in line with the balance of X chromosome gains
in these cells already described, with fluorescence in situ hybridization (FISH) analysis depicting a
higher X chromosome content for NT2 (three chromosomes) as compared to the other cell lines (two
chromosomes) [12]. The higher dosage of X chromosomes in the NT2 results is accompanied by a higher
relative degree of XIST demethylation, allowing for inactivation of the extra X chromosome material.
As mentioned above, XIST expression in males is restricted to particular stages of the germ
cell lineage, however, it is dependent on the extent of spermatogenesis. As demonstrated before,
XIST is not expressed in the testis with only premeiotic cells or in the case of Sertoli-cell only
syndrome, but starts to be expressed around the time germ cells enter meiosis [17,18]. Although
some suggest this re-expression of XIST might be necessary for a healthy spermatogenesis, recent
data have suggested a XIST-independent mechanism for X chromosome inactivation specifically
during spermatogenesis [30,31]. Regardless of that, XIST expression was indeed not detected in
atrophic testis parenchyma lacking spermatogenesis and GCNIS, but was detected in parenchyma
with active spermatogenesis and epididymis [12]. To the best of our knowledge, the assessment of
XIST methylation status has not been assessed in testis parenchyma samples for means of comparison
with Johnsen’s score. Our results demonstrate frequent demethylation of XIST promoter in testis
samples with active spermatogenesis, in the absence of GCNIS or overt TGCT. Indeed, no significant
differences in the relative amounts of demethylated XIST fragment were witnessed between TGCTs
and testicular parenchyma samples, in the discovery cohort (Supplementary Figure S1); however, this
was seen at the expense of the samples with normal, active spermatogenesis, as indicated by a higher
Johnsen’s score. When setting a cutoff at Johnsen’s score 4 (with scores of 1 to 3 corresponding to the
absence of postmeiotic germ cells, i.e., complete atrophy/sclerosis, Sertoli-cell only, and spermatogonia
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only, respectively, and scores ≥4 already containing increasingly more postmeiotic germ cells, from
spermatocytes to spermatids and spermatozoon), demethylated XIST fragment was almost absent in
samples with scores <4 in our discovery cohort, consistent with no expression of XIST. In line with this,
we set out to look for a correlation between the amount of demethylated XIST and the Johnsen’s score,
which we found and proved to be a significant and strong positive correlation (Figure 8). Validation of
our findings was again pursued; in both the discovery and validation independent cohorts the relative
amount or percentage of demethylated XIST was significantly higher in cases regarded as having a
Johnsen’s score ≥4 (i.e., where postmeiotic germ cells were identified by the pathologist on routine
examination) (Figure 8). Importantly, the amount or percentage of demethylated XIST (assessed by
two techniques, both regular quantitative methylation specific PCR (qMSP) using SYBR green dye and
high-resolution melting (HRM) methylation-sensitive analysis) was able to discriminate patients with
higher (≥4) and lower (<4) Johnsen’s score with good performance (AUC = 0.87–0.89, and remarkably
100% specificity in the discovery cohort).
4. Materials and Methods
4.1. Discovery Cohort
4.1.1. Testicular Germ Cell Tumor and Testicular Parenchyma Samples Selection
A cohort (already described and validated in [25]) of TGCT patients consecutively diagnosed at
the Portuguese Oncology Institute of Porto between 2005 and 2017 was included in the study. Hence,
a total of 156 GCNIS-related (type II) TGCT patients were included. All patients were operated on
and subsequently treated at this Institution by the same multidisciplinary team. Both clinical files
and histological data were reviewed according to the most recent 8th edition of the American Joint
Committee on Cancer (AJCC) staging manual [32] and the 2016 World Health Organization (WHO)
Classification of Tumors of the Urinary System and Male Genital Organs, respectively [7]. Patients
with metastatic disease were further categorized according to the IGCCCG prognostic system [33,34].
Follow-up was last updated on May 2019.
From these patients, formalin-fixed paraffin-embedded (FFPE) orchiectomy tissue samples (prior
to any systemic treatment) were available, and representative blocks were selected by a TGCT-dedicated
pathologist. A minimum of 80% tumor cellularity and absence of extensive necrosis were required in
the selection of blocks. Consultation cases and cases without adequate histological material available
were excluded. Importantly, individual tumor areas were carefully macro-dissected (in a strategy
already reported in [35–37]) and each component of mixed tumors was considered as an independent
sample for further analyses. Hence, a total of 250 independent tumor samples (106 SE, 56 EC, 36 YST,
11 CH, and 41 TE) were included in the study.
Additionally, a cohort of 54 patients undergoing orchiectomy for non-TGCT pathology (including
inflammatory disease, benign neoplasms such as Leydig cell tumors or adenomatoid tumors,
and surgical castration in the context of prostate cancer) were selected. Slides were reviewed
by an uropathology-dedicated pathologist and a Johnsen’s score was attributed to each case,
as described [20,21]. All slides were systematically screened for the presence of GCNIS (with
immunohistochemistry aid if needed), which was absent in all cases. Representative FFPE blocks of
the testicular parenchyma were selected.
Ten micrometer sections were then ordered for DNA extraction. This study was approved by
the ethics committee of the Portuguese Oncology Institute of Porto (Comissão de Ética para a Saúde—
CES-IPO-1-2018).
4.1.2. DNA Extraction and Bisulfite Treatment
DNA was extracted from the FFPE samples using RNA/DNA Purification Plus Kit (Norgen,
Thorold, ON, Canada), according to manufacturer’s instructions. The DNA quantification and purity
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were assessed in NanoDropTM Lite Spectophotometer. Sodium bisulfite treatment of 1000 ng of
genomic DNA was performed using a EZ DNA Methylation GoldTM Kit (Zymo Research, Irvine, CA,
USA), according to manufacturer’s protocol.
4.1.3. Methylation Analyses
The qMSP was performed using the same primers for demethylated and methylated region IV of
the XIST promoter reported by Kawakami et al. [13]. β-Actin (ACTB) was used for normalization as
previously reported and using the same primers described in the literature [38]. DNA amplification
was detected using SYBR Green-dye and a melting curve was generated to assess the presence of
nonspecific PCR products and primer-dimer. Reactions were carried out in 96-well plates using an
ABI 7500 Real Time PCR System (40 cycles). In brief, 1 µL of modified DNA, 5 µL of Xpert Fast SYBR
(GRISP), ROX, a variable volume of primers (0.3 µL for methylated and demethylated XIST, 0.4µL
for β-actin), and sterile bi-distilled water in a total volume of 10 µL were added to each well. Primer
annealing temperature was optimized at 64 ◦C for methylated and demethylated XIST and 60 ◦C for
β-actin. For quantification purposes, five serial dilutions (in duplicate) of previously bisulfite treated
CpGenomeTM Universal Methylated DNA and Unmethylated DNA (Merck Millipore, Burlingtone,
MA, USA) were included for methylated and demethylated XIST, respectively. A standard curve was
then generated which allowed for relative quantification. Reaction efficiency was above 90% in all
plates which allowed for interpolate comparisons. All experiments on FFPE samples were carried
out in triplicate and two negative controls were included in each plate. Relative levels of methylated
and demethylated XIST were determined using the formula: methylation level = (target gene/β-actin),
which was then multiplied by 1000 for easier tabulation.
4.2. Validation Cohort
4.2.1. Testicular Germ Cell Tumor and Testicular Parenchyma Samples Selection
A second, independent, validation cohort was included in the study. It included a cohort of
frozen tissue from 146 TGCT patients (64 pure SE and 82 NS, comprising 38 mixed tumors, 30 pure EC,
4 pure YST, 4 pure CH, and 6 pure TE), and also 17 frozen tissue sections from GCNIS (without overt
TGCT). Tissue samples were collected from several hospitals across the Netherlands and immediately
frozen at −80 ◦C. All samples corresponded to orchiectomy specimens of patients not subjected to
any systemic treatments. Sections were ordered for histological examination by the same experienced
TGCT-dedicated pathologist (J. Wolter Oosterhuis).
Additionally, a total of 32 testis biopsies which had been performed for infertility issues were
included. They corresponded to FFPE tissue which was reviewed by a uropathology-dedicated
pathologist and a Johnsen’s score was attributed to each sample. No sample depicted GCNIS lesions.
Use of patient samples remaining after diagnosis was approved for research by the Medical Ethical
Committee of the EMC (the Netherlands), permit no. 02.981. This included permission to use the
secondary samples without further consent. Samples were used according to the “Code for Proper
Secondary Use of Human Tissue in The Netherlands” developed by the Dutch Federation of Medical
Scientific Societies (FMWV, version, 2002; update 2011).
4.2.2. Cell Lines
The (T)GCT cell lines TCam-2, NT2, NCCIT, and 2102Ep were cultured as previously described
in [39]. Briefly, they were cultured at 37 ◦C in a humidified cell-culture incubator with 5% CO2. TCam-2
was grown in RPMI and the remaining cell lines in DMEM media (both with 10% fetal bovine serum
and 1% penicillin/streptomycin) (GIBCO, Invitrogen, Carlsbad, CA, USA).
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4.2.3. DNA Extraction and Bisulfite Treatment
The DNeasy Blood and Tissue Kit (Qiagen) and the phenol-chloroform method were used for DNA
extraction from frozen tumors, cell lines, and FFPE samples. After that, sodium bisulfite treatment
ranging from 500–1000 ng of genomic DNA was performed using EZ-96 DNA Methylation-Gold Kit
(Zymo Research, Irvine, CA, USA), according to the manufacturer’s protocol.
4.2.4. Methylation Analysis (High-Resolution Melting)
For the validation series, a more sensitive method was employed to improve preliminary results
in the discovery cohort, and therefore the HRM methylation study [40,41] was performed to determine
the precise percentage of demethylated XIST fragment. Bisulfite-specific primers for the region IV of
the XIST promoter were designed using Methyl Primer Express® Software (Applied Biosystems, Foster
City, CA, USA), as indicated by the manufacturers (forward: 5′ TGTTGTTGATTATTTGGTGGT 3′ and
reverse: 5′ TACCTCCCTAATTTAACTTAACACAA 3′). As in the previous experiment, β-actin was
used as the control for bisulfite-treatment. The DNA amplification was detected using MeltDoctor™
HRM dye and a melting curve was generated. Real-time quantitative PCR (RT-qPCR) was performed
in 96-well plates, using a QuantStudio 12K Flex Real-Time PCR System (ThermoFisher), with 40 cycles
for fresh frozen tissue and cell lines and 50 cycles for FFPE. 1.25 µL (for fresh frozen tissue samples
and cell lines) and 2.5 µL (for FFPE samples) bisulfite-treated DNA, 10 µL MeltDoctor™ HRM Master
Mix, 0.6 µL of forward and reverse primers (10µM solutions), and sterile bi-distilled water in a total
volume of 20 µL were added to each well. Primer annealing temperature was optimized at 63 ◦C.
For each target sequence a no template control was included and male and female DNA samples
(from peripheral blood lymphocytes) were included in each plate as additional controls. Importantly,
the percentage of demethylated XIST was quantified using 0, 2%, 5%, 10%, 25%, 50% and 100%
demethylated DNA standards that were generated by mixing different ratios of bisulfite-treated 100%
methylated and 100% non-methylated Human HCT116 DKO DNA (ZymoResearch, Irvine, CA, USA),
as recommended by the manufacturers.
4.3. Statistical Analysis
Data was tabulated using Microsoft Excel 2016 and analyzed using IBM SPSS Statistics version 24
and GraphPad Prism 6. Differences in relative methylation and demethylation among groups were
assessed by the non-parametric Mann–Whitney U test and Kruskal–Wallis test, as appropriate. Cell
lines were compared with unpaired t-test or ordinary one-way ANOVA, as appropriate. Associations
between categorical variables were determined by means of a Chi-square test. All p-values were
adjusted to multiple testing by Dunn’s or Turkey’s test, as appropriate. In patients diagnosed with
mixed TGCT, the highest methylation value among all components was considered for assessing
associations with clinicopathological features. Methylation data was correlated with patients’ age
and Johnsen’s score using the Spearman non-parametric correlation test. Biomarker performance was
assessed through receiver operating characteristics (ROC) curve construction. For both methylated
and demethylated XIST, the Youden’s method [42,43] was used to achieve a cutoff to maximize the
sensitivity and specificity. In addition, area under the curve (AUC), sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV), and accuracy were ascertained for both
targets. Statistical significance was set at p-value < 0.05.
5. Conclusions
To conclude, we have provided evidence on the value of determining the XIST promoter
methylation status both for diagnosis of TGCTs and for assessment of spermatogenesis extent. Some
limitations of our work include its retrospective nature and the focus on tissue samples. However,
we have gathered the largest cohort of TGCTs thus far focusing on studying XIST demethylation,
and have replicated our data in a second, large independent cohort, reinforcing the strength of our
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results. In addition, we have employed two different techniques to achieve the same conclusions,
including high-resolution melting methylation analyses, which improved the overall detection of XIST
demethylated fragment.
Better TGCT biomarkers amenable for detection in liquid biopsies are needed to complement
the current available serum tumor markers. On the basis of the results on the tissues discussed, we
believe that detection of XIST demethylation is a promising candidate and we intend to pursue its
detection in a large cohort of serum or plasma samples from TGCT patients. Moreover, Johnsen’s score
is a laborious and limited methodology for assessing spermatogenesis in testicular biopsies and for
clinical decision making. Given the correlation with spermatogenesis efficiency, assessment of XIST
demethylation levels in semen samples from infertile patients will be of interest as a non-invasive way
for better grouping of these patients and deciding on the best treatment option.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/9/1385/s1:
Supplementary Figure S1. Demethylated XIST fragment relative amounts in testicular germ cell tumors and
testicular parenchyma of the discovery cohort. Relative amounts of the demethylated XIST fragment among
testicular parenchyma samples and (A) all TGCT samples; (B) all SE samples; (C) only pure SE samples;
and (D) all NS samples. Abbreviations: NS—non-seminoma; SE—seminoma; TGCT—testicular germ cell
tumor; Supplementary Figure S2. Demethylated XIST fragment relative amounts in seminoma and embryonal
carcinoma patients of the discovery cohort. ** indicates p < 0.01. Abbreviations: EC—embryonal carcinoma and
SE—seminoma; Supplementary Figure S3. XIST methylation and expression and X chromosome inactivation
in humans. (A) Methylation status of the XIST promoter in somatic male cells (XY, both allelles methylated, no
expression), in female somatic cells (XX, there is XIST demethylation and expression), and in TGCTs (gains of X
chromosome, there is XIST demethylation and expression) and (B) mechanism of X chromosome inactivation,
starting with transcription of the XIST lncRNA (encoded in the X chromosome inactivation centers) which
induces chromatin modifications resulting in silencing of redundant X chromosome genes. Abbreviations: XIC—X
inactivation centers; Xa—activated X chromosome; Xi—inactivated X chromosome; Supplementary Table S1
Clinicopathological features of testicular germ cell tumor cases in the discovery cohort; Supplementary Table S2
Clinicopathological features of testicular germ cell tumor cases in the validation cohort; Supplementary Table
S3 Clinicopathological features of non-germ cell tumor cases in the discovery cohort; Supplementary Table S4
Clinicopathological features of patients undergoing testicular biopsy for infertility issues in the validation cohort.
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